What is the new schizophrenia drug COBENFY?: A Breakthrough in Treatment
•
4 min read
Affecting about 1% of the population, schizophrenia has been treated largely with dopamine-targeting medications for decades. The recent FDA approval of **COBENFY**, a new schizophrenia drug, marks a significant shift with its novel, non-dopamine mechanism of action. This first-in-class muscarinic agonist represents a new pharmacological approach to managing schizophrenia symptoms in adults.
